Terns Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Terns Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($24.64M) | Nov 10, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($24.09M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($24.09M) | Aug 5, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($23.91M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($23.91M) | May 8, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($23.91M) | Nov 10, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($21.95M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($22.74M) | Aug 5, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($22.74M) | Nov 10, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($22.37M) | Nov 10, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($22.37M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($22.37M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($29.77M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($17.90M) | Aug 5, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($17.90M) | Nov 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($21.53M) | May 13, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($21.53M) | Nov 12, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($21.53M) | Aug 5, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($16.82M) | Nov 14, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($13.93M) | Nov 14, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($27.72M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($27.38M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($27.43M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($24.94M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($25.54M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($25.45M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($33.18M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($21.16M) | Aug 5, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($24.16M) | May 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($17.29M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($14.08M) | Aug 8, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($13.83M) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($11.87M) | Nov 9, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($10.82M) | Aug 8, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($13.30M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($8.74M) | Nov 15, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($10.10M) | Aug 16, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($9.42M) | May 14, 2021 |